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Abstract It has been recently shown that cannabinoids may
regulate the growth of many cell types. In the present work
we examined the e¡ect of the anandamide analogue (R)-meth-
anandamide (MET) on androgen-dependent prostate LNCaP
cell growth. We found that 0.1 WM MET had a mitogenic e¡ect
measured by [3H]thymidine incorporation into DNA. The e¡ect
exerted by MET was blocked by the cannabinoid receptor an-
tagonists SR141716 (SR1) and SR144528 (SR2) as well as by
the phosphoinositide 3-kinase (PI3K) inhibitor LY294002, sug-
gesting an involvement of cannabinoid receptors and the PI3K
pathway in the mechanism of MET action. MET treatment of
LNCaP cells also induced an up-regulation of androgen receptor
expression that was blocked by the two cannabinoid receptor
antagonists SR1 and SR2. These results show for the ¢rst time
that cannabinoids may modify androgen receptor expression in
an androgen-dependent cell line and by this mechanism could
regulate prostate cell growth.
; 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The principal psychoactive ingredient of marijuana is v9-
tetrahydrocannabinol (THC), which exerts many of its biolog-
ical e¡ects through binding to speci¢c cannabinoid receptors
expressed in cellular membranes. Recently, endogenous sub-
stances that bind to the same receptors as Cannabis sativa-
derived compounds have been identi¢ed and they have been
called endocannabinoids [1,2], arachidonoylethanolamide (an-
andamide) being the ¢rst endocannabinoid to be isolated [3].
Cannabinoid receptors described to date include two cloned G
protein-coupled receptors named CB1 and CB2 as well as one
non-selective cation channel known as vanilloid receptor sub-
type 1 [4,5]. Many intracellular transduction systems may be
triggered by cannabinoids upon receptor binding. CB1 and
CB2 are negatively coupled to adenylyl cyclase through Gi=o
proteins in many cells and tissues inducing a general inhibi-
tion of the cAMP/protein kinase A (PKA) signalling pathway
[6,7]. Activation of the mitogen-activated protein kinase
(MAPK) cascade by cannabinoids has also been demonstrated
both in vitro [6,8] and in vivo [9], suggesting a role for can-
nabinoids in the regulation of cellular fate [10]. In fact, can-
nabinoid agonists have been shown to induce the death of
some transformed neuronal and non-neuronal cells while exert
a protective action in normal neurons [11^14]. However, at
sub-micromolar concentrations, cannabinoids may stimulate
proliferation of lymphocytes [15] and prostate PC-3 cells
[16] and recent evidence suggests that the CB2 cannabinoid
receptor may be a novel oncogene [17].
Prostate cell proliferation is regulated by many extracellular
and intracellular factors including steroid hormones, neuro-
peptides and growth factors [18]. In men, the primary circu-
lating androgen is testosterone secreted by the testes under
hypothalamic^pituitary regulation and it is required for nor-
mal growth and functional activities of the prostate. In the
prostate, testosterone is converted to the more potent 5K-di-
hydrotestosterone (DHT) by the enzyme 5K-reductase [19].
The actions of both testosterone and DHT are mediated by
the intracellular androgen receptor that binds to androgen-
responsive elements in genes to regulate gene transcription
[20]. Tumoral transformation results from a multi-step process
which is mainly under androgenic control and therefore inhi-
bition of androgen action is one of the standard therapies for
metastatic prostate cancer. Most prostate cancers initially re-
spond to hormonal therapy, but after a limited period of
relapse, cancer recurs as an androgen-independent disease
[21]. LNCaP is an androgen-responsive cell line derived
from a metastatic lesion of the lymph nodes of a patient
with con¢rmed diagnosis of prostate cancer. It has been
widely used to study the regulation of the androgen receptor
which contains a mutation in the ligand binding domain
[22,23]. Androgen receptor is up-regulated upon DHT treat-
ment in LNCaP cells with the involvement of MAPK activa-
tion and the phosphoinositide 3-kinase (PI3K)/Akt pathway
[24]. We have previously demonstrated that cannabinoids may
activate the PI3K and MAPK cascade in prostate cells [16].
The present work was undertaken to study the role of canna-
binoids in the regulation of LNCaP cell growth and the in-
volvement of the androgen receptor in the e¡ect of cannabi-
noids. We show here that (R)-methanandamide (MET) at
nanomolar concentrations stimulates the DNA synthesis in
LNCaP cells via a cannabinoid receptor-dependent mecha-
nism.
2. Materials and methods
2.1. Materials
MET, HU-210 and JWH-015 were purchased from Tocris (Bristol,
UK). THC and DHT were from Sigma (St. Louis, MO, USA). Can-
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nabinoid receptor antagonists SR141716 (SR1) and SR144528 (SR2)
were a kind gift from Sano¢ Recherche (Montpellier, France). En-
zyme inhibitors LY294002, PD98059, 8-bromoadenosine 3P,5P-cyclic
monophosphothioate (BrA), 8-bromoadenosine 3P,5P-cyclic mono-
phosphothioate Rp isomer (BrARpI) and bisindolylmaleimide I
(BIM) were from Alexis Corporation (San Diego, CA, USA).
SB203580 was from Tocris. Anti-human androgen receptor monoclo-
nal antibody was from Becton Dickinson Biosciences (San Diego, CA,
USA). Other agents were from Sigma.
2.2. Cell cultures
Human prostate LNCaP cells were purchased from American Type
Culture Collection (ATCC CRL 1740) (Rockville, MD, USA). They
were routinely grown in RPMI 1640 medium supplemented with 5%
fetal calf serum. For experiments, cell passages between 3 and 10 were
used. Cells were seeded at 30 000 cells/cm2 and grown for 2 days.
Twenty-four hours before the experiment, the serum-containing me-
dium was removed and a chemically de¢ned medium consisting of
RPMI 1640 supplemented with 5 Wg/ml insulin, 5 Wg/ml transferrin
and 5 ng/ml sodium selenite was added.
2.3. [3H]Thymidine incorporation
Cells were treated with di¡erent concentrations of MET according
to the experiment. DNA synthesis was determined by pulsing the cells
with [3H]thymidine (1 WCi/well) for the last 16 h of the culture period.
After extensive washing, cells were incubated with 10% trichloroacetic
acid for 15 min at 4‡C and then neutralized with 1 N NaOH for 1 h.
Radioactivity incorporated was monitored by liquid scintillation.
2.4. Western blot
Cultured cells were treated according to the experimental condi-
tions, lysed into lysis bu¡er (50 mM Tris^HCl, pH 7.4, 5 mM
EDTA, 1 mM EGTA, 10 mM 2-mercaptoethanol containing 5 Wg/
ml leupeptin, 5 Wg/ml aprotinin, 10 Wg/ml soybean trypsin inhibitor
and 1 mM phenylmethylsulfonyl £uoride) and disrupted by sonica-
tion. 20 Wg of cellular lysates were loaded into acrylamide gels and
proteins were separated by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis after which they were electrophoretically transferred to
a nitrocellulose membrane. Membranes were blocked with 3% fat-free
milk and incubated with anti-human androgen receptor (1:500 dilu-
tion) overnight at 4‡C. Then, membranes were incubated for 1 h with
a secondary horseradish peroxidase-conjugated antibody and devel-
oped with ECL luminescent substrate (Amersham, UK).
3. Results
3.1. E¡ect of cannabinoids on LNCaP cell proliferation
The e¡ect of cannabinoids on cellular proliferation was
studied by [3H]thymidine incorporation into DNA using the
anandamide analogue MET which possesses a higher potency
and metabolic stability than anandamide [25]. Addition of
increasing MET concentrations to cultured LNCaP cells in-
duced a mitogenic e¡ect that peaked at 0.1^0.2 WM (Fig. 1A).
Doses of MET over 1 WM induced cellular death (data not
shown). The mitogenic e¡ect induced by MET was maximal
at 4 days treatment, after which cell growth stopped and cells
began to di¡erentiate (Fig. 1B and data not shown).
In order to evaluate the involvement of cannabinoid recep-
tors in the response induced by MET, the growth test was
performed in the absence or presence of the CB1 receptor
antagonist SR1 and the CB2 receptor antagonist SR2. We
have previously demonstrated by Western blot that LNCaP
cells express both CB1 and CB2 cannabinoid receptors [16]. As
shown in Fig. 2, pre-incubation of LNCaP cell with either
SR1, SR2 or both antagonists together blocked the prolifer-
ative response induced by MET. Moreover, the cannabinoid
receptor antagonists alone or in combination with MET re-
duced the [3H]thymidine incorporation into DNA to below
the control values (Fig. 2), which is in concordance with the
inverse agonist properties proposed for these compounds
[26,27].
We next tested the ability of other cannabinoid agonists to
induce cellular proliferation of LNCaP prostate cells. THC,
which is an agonist for both CB1 and CB2, HU-210 which is
Fig. 1. E¡ect of MET on LNCaP cell proliferation. (A) Cells were
incubated with di¡erent doses of MET during 4 days after which
[3H]thymidine incorporation into DNA was measured by liquid
scintillation. (B) Cells were incubated with 0.1 WM MET for 2, 4 or
8 days. Data are meansRS.D. of four di¡erent experiments per-
formed in triplicate and are expressed as percent over control.
*P6 0.1; **P6 0.005 compared with the corresponding controls.
Fig. 2. E¡ect of cannabinoid receptor antagonists on the mitogenic
response induced by MET in LNCaP cells. Cells were treated with
di¡erent doses of MET in the presence or absence of 0.5 WM SR1,
0.5 WM SR2 or both together for 2 days. Data are meansRS.D. of
two di¡erent experiments performed in triplicate and are expressed
as percent over control. *P6 0.001 compared with the correspond-
ing MET treatment.
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more potent than THC, and JWH-015, which is a CB2 agonist
[28], also exerted a mitogenic e¡ect that was maximal at 0.1
WM concentration (Fig. 3). The CB2 agonist JWH-015 inhib-
ited cellular growth at doses over 0.5 WM, which is lower than
THC, HU-210 and MET, providing the basis for future in-
vestigations studying the role of CB2 in the antiproliferative
response of high doses of cannabinoids.
3.2. E¡ect of various enzyme inhibitors on the proliferative
response induced by MET
To investigate the mechanism whereby MET induces cellu-
lar proliferation we used various inhibitors of several intra-
cellular transduction pathways (Table 1). The di¡erent inhib-
itors, when added alone, had no e¡ect on cell viability with
the exception of SB203580, a highly selective inhibitor of
MAPK, which increased cell proliferation, suggesting that in
LNCaP cells, the p38 MAPK pathway may probably be acti-
vated in basal conditions.
We have previously demonstrated that cannabinoids acti-
vate the MAPK cascade in prostate PC-3 cells via PI3K acti-
vation [16,29] and therefore we investigated whether these
intracellular pathways were also activated in LNCaP cells.
The mitogenic e¡ect elicited by MET was blocked by the
addition of LY294002, an inhibitor of PI3K, and by the ad-
dition of PD98059, a selective inhibitor of the extracellular
signal-regulated kinase kinase (Table 1). These results suggest
that MET activates both intracellular pathways in LNCaP
cells and in these ways exerts its mitogenic e¡ect.
It has previously been shown that cannabinoids activate the
stress-related p38 MAPK in some cells [30]. So, we tested the
ability of the p38 inhibitor SB203580 to block the pro-survival
e¡ect of MET in LNCaP cells. Addition of 50 WM SB203580
to cultured cells did not signi¢cantly block the e¡ect of MET
(Table 1) suggesting that the mitogenic e¡ect of MET is in-
dependent of this pathway. Similar results were obtained with
the PKA activator BrA or the PKA inhibitor BrARpI. None
of them a¡ected the mitogenic e¡ect induced by MET (Table
1). This was not the case for the PKC inhibitor BIM which
totally blocked the pro-survival e¡ect of MET (Table 1).
3.3. E¡ect of MET on the expression of the androgen receptor
in LNCaP cells
The LNCaP cell line depends on androgens for growth.
Androgens, through binding to the androgen receptor ex-
pressed in these cells, promote cellular proliferation. There-
fore, we next tested the e¡ect of MET on androgen receptor
expression determined by Western blotting. MET at 0.1 WM
concentration increased the expression of androgen receptor
Fig. 3. E¡ect of exogenous cannabinoids on LNCaP cell prolifera-
tion. Cells were incubated with di¡erent doses of THC, HU-210
and JWH-015 for 2 days after which [3H]thymidine incorporation
into DNA was measured by liquid scintillation. Data are
meansRS.D. of two di¡erent experiments performed in triplicate
and are expressed as percent over control.
Table 1
E¡ect of di¡erent enzyme inhibitors on the mitogenic action of MET in LNCaP cells
[3H]Thymidine incorporation (cpm) %
No addition 78 072R 16 679 100
0.1 WM MET 164 443R 17 209# 210R22
10 WM LY294002 85 861R 15 098 109R19
0.1 WM MET+10 WM LY294002 79 104R 14 437** 101R10
0.1 WM PD98059 78 682R 8 960 100R11.4
0.1 WM MET+0.1 WM PD98059 92 020R 6 483* 117R8.3
50 WM SB203580 126 905R 16 374 162R20
0.1 WM MET+50 WM SB203580 137 371R 1 702 175R2
50 WM BrA 79 845R 3 998 102R5
0.1 WM MET+50 WM BrA 154 130R 42 591 197R54
50 WM BrARpI 96 457R 19 487 123R24
0.1 WM MET+50 WM BrARpI 141 078R 10 370 180R13
2 WM BIM 78 553R 14 337 100R18
0.1 WM MET+2 WM BIM 79 147R 28 791** 101R13
Cells were pre-incubated with the di¡erent agents for 10 min and then incubated with 0.1 WM MET for 4 days, after which [3H]thymidine in-
corporation into DNA was measured by liquid scintillation. Data are meansRS.D. of two di¡erent experiments performed in triplicate.
*P6 0.05; **P6 0.001 vs. 0.1 WM MET; #P6 0.0001 vs. no addition as assessed by the paired Student’s t-test.
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in LNCaP cells which was maximal at 2 days treatment (Fig.
4). The fact that the maximal induced expression of the an-
drogen receptor was earlier than the maximal MET-induced
mitogenic e¡ect, which was at 4 days, suggests that the mito-
genic e¡ect induced by MET could be mediated by the in-
crease in the androgen receptor.
We then examined the involvement of the cannabinoid re-
ceptors in the action of MET. Treatment of cells with the CB1
antagonist SR1 reversed the e¡ect produced by MET at 2 and
4 days treatment (Fig. 5A). As shown in Fig. 5B, the e¡ect
induced by MET was dose-dependent and was inhibited by
SR1 at the three doses studied. Treatment with the CB2 an-
tagonist SR2 also reversed the androgen receptor induction by
MET at 2 days (Fig. 6A) and low doses of treatment (Fig.
6B). However, the CB2 antagonist did not signi¢cantly block
the MET-induced androgen receptor up-regulation at 4 days
or at 5 WM MET (Fig. 6).
4. Discussion
It has been recently shown that endocannabinoids may reg-
ulate cellular fate [10,31]. Depending on cell type and canna-
binoid concentration, cannabinoids may induce either cell
death or cell growth. At doses greater than micromolar, can-
nabinoids inhibit the growth of prostate cells [32^34] whereas
at submicromolar concentrations, cannabinoids activate mito-
genic signal transduction pathways [16]. Here, we show that
the endocannabinoid anandamide analogue MET, at submi-
cromolar concentration, had a mitogenic e¡ect in prostate
LNCaP cells and increased the expression of the androgen
receptor in these cells. The maximal e¡ect produced by
MET was observed at 0.1^0.2 WM and at 4 days of treatment.
At longer incubation periods, cell growth was reduced and
cells began to di¡erentiate. The e¡ect of MET was mediated
by the cannabinoid receptors CB1 and CB2 and the activation
of the PI3K and MAPK pathways. We have previously dem-
onstrated that cannabinoid receptors activate the MAPK cas-
cade through stimulation of the PI3K/Akt pathway in pros-
tate cells [16]. Here, we show that the activation of this
pathways leads to the stimulation of prostate LNCaP cell
growth.
Cannabinoid receptors are coupled to adenylyl cyclase
through G proteins. In most cells, cannabinoids inhibit ade-
nylyl cyclase although under certain conditions they may stim-
ulate the enzyme. However, the observed MET-induced mito-
genic e¡ect in LNCaP cells was independent of the cAMP
pathway, since neither PKA activator nor PKA inhibitor af-
fected the e¡ect induced by MET. On the other hand, the fact
Fig. 4. E¡ect of MET on androgen receptor expression in LNCaP
cells. Cells were treated with 0.1 WM MET for di¡erent days and
androgen receptor expression was determined by Western blot. The
¢gure shows a representative image of three independent experi-
ments. Actin expression was also determined as a control. Densito-
metric analysis of three independent experiments, expressed as per-
cent over control at 1 day, is represented in the histogram.
*P6 0.01; **P6 0.0005 compared with the corresponding controls.
Fig. 5. Inhibition of the MET-induced up-regulation of the an-
drogen receptor in LNCaP cells by CB1 cannabinoid antagonist.
(A) Cells were treated with 0.1 WM MET for di¡erent days in the
presence or absence of 0.5 WM SR1. (B) Cells were treated with dif-
ferent doses of MET in the presence or absence of 0.5 WM SR1 for
2 days. The ¢gure shows a representative image of two independent
experiments. Actin expression was also determined as a control.
Densitometric analysis of two independent experiments, expressed as
percent over control at 2 days, is represented in the histogram.
*P6 0.005 compared with the corresponding control; #P6 0.05
compared with MET treatment.
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that the protein kinase C (PKC) inhibitor BIM blocked the
e¡ect of MET points to an involvement of PKC in the mito-
genic response induced by cannabinoids in prostate cells. This
pathway will be further explored in our laboratory.
MET also induced an increase in the androgen receptor
expression that was mediated by the CB1 receptor under all
conditions studied and partially by CB2 receptor activation.
Although the CB2 antagonist was able to reverse the e¡ect
induced by MET at low doses of MET (0.1 WM) and short
periods of incubation (2 days), the up-regulation of androgen
receptor at higher MET concentrations or longer times seems
to be CB2-independent. In fact, the mitogenic response in-
duced by the CB2 agonist JWH-015 was less prominent
than the response induced by the other agonists tested (Fig.
3).
All these results are in agreement with previous reports
showing that androgen receptor expression is regulated by
the PI3K/Akt pathway in LNCaP cells [24]. Therefore, one
possible mechanism for MET up-regulation of androgen re-
ceptor could be the stimulation of the PI3K/Akt pathway.
The enhancement of androgen receptor levels could explain
the proliferative e¡ect of MET, since LNCaP cells depend on
androgens for growth. One interesting point is the fact that
some androgens like DHT or the synthetic androgen R1881
exert a peculiar biphasic dose-dependent in£uence on the pro-
liferation of LNCaP cells [35] similar to the action of canna-
binoids. DHT induces an up-regulation of the androgen re-
ceptor in these cells even at micromolar concentrations [24]
that inhibit cell growth [35], which is in concordance with our
results. Therefore, in prostate LNCaP cells, cannabinoids, act-
ing via cannabinoid receptors and the PI3K pathway, could
modulate cellular growth through the regulation of androgen
receptor levels.
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